Johnson & Johnson, the healthcare and lifestyle giant announced a more than $1 billion dollar investment in next generation cell therapy. The company will invest this sum in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
The new site will further expand its U.S. manufacturing capacity as it advances its industry-leading portfolio and pipeline of transformational medicines for cancer, immune-mediated, and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
READ: Jury orders Johnson & Johnson to pay $966 million over talc-linked cancer death (
The announcement is part of the Company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.
“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Governor Josh Shapiro. “Just a few years ago we weren’t even on the field – but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in two decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth – because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
“Pennsylvania leads in life sciences and advanced manufacturing because we consistently deliver what companies like Johnson & Johnson need to succeed: a skilled workforce, premier research institutions, and proven manufacturing strength,” said U.S. Senator Dave McCormick. “This $1 billion-plus investment in a new Lower Gwynedd facility is a testament to that leadership and will produce life-changing treatments for patients, along with new and good jobs for our Commonwealth.”
What is next generation cell therapy?
Next-generation cell therapy refers to advanced medical treatments that use living cells to repair, replace, or enhance damaged tissues and organs in ways that traditional therapies cannot. Unlike first-generation approaches, which often relied on simple stem cell transplants or immune cell infusions, next-generation therapies are engineered for higher specificity, durability, and functionality.
Examples include CAR-T cells, where a patient’s T cells are genetically modified to target cancer cells, or gene-edited stem cells designed to correct genetic disorders. Researchers are also exploring allogeneic “off-the-shelf” cell products, which can be manufactured in batches and used in multiple patients, reducing the time and cost associated with personalized treatments.
READ: Johnson & Johnson to pay $1.56 billion to a talc plaintiff in largest ever award (
These therapies often incorporate synthetic biology, genome editing, and tissue engineering to enhance safety, efficacy, and persistence in the body. Next-generation cell therapy holds promise for treating a wide range of diseases, including cancer, autoimmune disorders, neurodegenerative diseases, and organ failure, potentially transforming the landscape of modern medicine.
The development of new facilities and expansion of production capacity also supposedly signals broader confidence in the future of cell-based therapies and their potential to address previously intractable diseases.